As described above, several researchers have observed the dysregulated expression of SLC39A1 in prostate cancer, breast cancer, and colorectal cancer [8–10], while the differentiated expression in normal liver and EHCC tissues has not been summarized. Here, SLC39A1 is linked to prostate cancer.